# CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma

> **NCT02258815** · PHASE2 · COMPLETED · sponsor: **University Children's Hospital Tuebingen** · enrollment: 35 (estimated)

## Conditions studied

- Neuroblastoma Recurrent

## Interventions

- **DRUG:** ch14.18/CHO

## Key facts

- **NCT ID:** NCT02258815
- **Lead sponsor:** University Children's Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2018-11
- **Final completion:** 2022-12
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2023-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02258815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02258815, "CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02258815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*